phrykt

Tango Therapeutics, Inc. (TNGX): who owns it and who trades it

As of Nov 16, 2026, TNGX insiders reported 30 open-market sales worth $8.1M and no purchases in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adam Crystal (President), with $7.2M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Tango Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TNGX

246 funds and institutions reported TNGX shares worth $6.8B at the end of Q2 2026. The largest holder is Rtw Investments, LP with $435M.

10 largest owners, by value

Rtw Investments, LP$435M
BlackRock, Inc.$389M
FMR LLC (Fidelity)$386M
Farallon Capital Management, L.l.c.$384M
Boxer Capital Management, LLC$340M
Goldman Sachs Group Inc$312M
TCG Crossover Management, LLC$284M
Trv Gp Iv, LLC$120M
Paradigm Biocapital Advisors LP$199M
T. Rowe Price Associates$198M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Rtw Investments, LP13.90M–$435M+5%
BlackRock, Inc.12.44M–$389M+42%
FMR LLC (Fidelity)12.33M–$386M+25%
Farallon Capital Management, L.l.c.12.28M–$384M+35%
Boxer Capital Management, LLC10.88M–$340MNo change
Goldman Sachs Group Inc9.98M–$312M+97%
TCG Crossover Management, LLC9.08M–$284M-14%
Trv Gp Iv, LLC6.37M–$120MNo change
Paradigm Biocapital Advisors LP6.36M–$199M+59%
T. Rowe Price Associates6.35M–$198M+614%
Siren, L.L.C.6.18M–$193M+9%
State Street Corp5.98M–$187M+29%
Vanguard Capital Management LLC5.96M–$186M+15%
Adage Capital Partners Gp, L.l.c.5.60M–$175M-56%
Jupiter Topco LLC5.06M–$158M–
Deep Track Capital, LP4.20M–$131M+53%
Deerfield Management Company, L.P.4.19M–$131M+1%
Woodline Partners LP4.00M–$125M-50%
Geode Capital Management, LLC3.74M–$117M+40%
Perceptive Advisors LLC3.38M–$106M+318%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TNGX insiders reported $0 of open-market purchases and $8.1M of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$8.1M
30 trades, 4 people
Sales under a 10b5-1 plan
13%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$1.5M$1.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Adam CrystalPresidentSale plan5,000$25.00$125KForm 4
Nov 2, 2026Adam CrystalPresidentSale plan3,900$22.26$86.8KForm 4
Nov 2, 2026Adam CrystalPresidentSale plan1,100$22.99$25.3KForm 4
Nov 2, 2026Jessica NewcombPrincipal Accounting OffSale plan5,571$22.28$124KForm 4
Nov 2, 2026Jessica NewcombPrincipal Accounting OffSale plan1,460$22.98$33.6KForm 4
Oct 1, 2026Adam CrystalPresidentSale plan26,400$24.45$646KForm 4
Oct 1, 2026Adam CrystalPresidentSale plan600$25.32$15.2KForm 4
Sep 22, 2026Jessica NewcombPrincipal Accounting OffSale2,400$25.17$60.4KForm 4
Sep 22, 2026Jessica NewcombPrincipal Accounting OffSale5,100$23.97$122KForm 4
Sep 22, 2026Jessica NewcombPrincipal Accounting OffSale700$22.80$16KForm 4
Sep 1, 2026Adam CrystalPresidentSale27,000$22.37$604KForm 4
Aug 3, 2026Adam CrystalPresidentSale21,733$27.35$594KForm 4
Aug 3, 2026Adam CrystalPresidentSale5,267$26.79$141KForm 4
Jul 1, 2026Adam CrystalPresidentSale7,371$30.25$223KForm 4
Jul 1, 2026Adam CrystalPresidentSale19,629$29.34$576KForm 4
Jun 1, 2026Adam CrystalPresidentSale20,860$23.06$481KForm 4
Jun 1, 2026Adam CrystalPresidentSale6,140$22.25$137KForm 4
May 1, 2026Adam CrystalPresidentSale25,900$21.19$549KForm 4
May 1, 2026Adam CrystalPresidentSale1,100$22.00$24.2KForm 4
Apr 15, 2026Adam CrystalPresidentSale38,460$25.00$962KForm 4
Apr 1, 2026Adam CrystalPresidentSale27,000$21.20$572KForm 4
Mar 25, 2026Adam CrystalPresidentSale12,000$20.11$241KForm 4
Mar 5, 2026Adam CrystalPresidentSale20,251$15.00$304KForm 4
Feb 25, 2026Adam CrystalPresidentSale54,345$12.77$694KForm 4
Feb 3, 2026Daniella BeckmanCFOSale10,204$12.26$125KForm 4
Feb 3, 2026Daniella BeckmanCFOSale113$12.90$1.5KForm 4
Feb 3, 2026Barbara WeberChairSale333$12.90$4.3KForm 4
Feb 3, 2026Barbara WeberChairSale30,186$12.26$370KForm 4
Feb 3, 2026Adam CrystalPresidentSale201$12.90$2.6KForm 4
Feb 3, 2026Adam CrystalPresidentSale18,251$12.26$224KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Adam CrystalPresident, R&D–$7.2MNov 11, 2026
Barbara WeberDirector, Executive Chair, Director–$374KFeb 3, 2026
Jessica NewcombPrincipal Accounting Officer–$356KNov 2, 2026
Daniella BeckmanChief Financial Officer–$127KFeb 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TNGX short interest

Very high short interest. 28.6% of TNGX shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 52%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 48.24M TNGX shares were sold short, 28.6% of the shares outstanding, up 7.7% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 9.7 trading days (days to cover).

Shares short, % of all shares

28.6%May 15Oct 3032.6%

Days to cover

9.7May 15Oct 3023.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202648.24M28.61%+8%4.96M9.7
Oct 15, 202644.78M26.56%+1%4.01M11.2
Sep 30, 202644.50M26.39%+6%3.55M12.5
Sep 15, 202641.87M24.83%-2%2.23M18.8
Aug 31, 202642.63M25.28%-1%2.16M19.7
Aug 14, 202643.19M25.61%-3%2.06M20.9
Jul 31, 202644.61M31.26%+4%2.33M19.1
Jul 15, 202642.72M29.94%+2%2.79M15.3
Jun 30, 202642.01M29.44%+23%6.38M6.6
Jun 15, 202634.04M23.86%+2%6.27M5.4
May 29, 202633.49M23.47%+5%2.57M13.0
May 15, 202631.81M22.29%-17%3.18M10.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tango Therapeutics company events

Tango Therapeutics filed 17 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 23, 2026AnnouncementThe Company disclosed promising results from its ongoing Phase 1/2 trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. Filing
  3. Aug 11, 2026AnnouncementAs previously disclosed, on November 21, 2025, Tango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock… Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Aug 7, 2026LeadershipAmended an earlier report. Of the Original Form 8-K to include the terms of the executed separation agreement. Filing
  6. Aug 6, 2026LeadershipDr. Barbara Weber’s employment with Tango Therapeutics, Inc. as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026. Filing
  7. Jun 23, 2026LeadershipThe Board of Directors of Tango Therapeutics, Inc. increased the number of directors of the Company to seven (7). Filing
  8. Jun 10, 2026AgreementTango Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives to the several underwriters named in the Underwriting Agreement, relating to an underwritten offering of (i) 18,166,667 shares of the Company’s common stock… Filing
  9. Jun 8, 2026AnnouncementThe Company disclosed initial safety and efficacy data from its Phase 1/2 combination trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma. Filing
  10. Jun 4, 2026VoteReported shareholder vote results. Filing
  11. May 13, 2026LeadershipAlexis Borisy resigned from the Company’s Board of Directors, as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board and as a member thereof, in each case effective as of May 13, 2026. Filing
  12. May 8, 2026LeadershipSeparation Agreement As previously announced, on April 10, 2026, the board of directors of Tango Therapeutics, Inc. determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15… Filing
  13. Apr 15, 2026LeadershipThe board of directors of Tango Therapeutics, Inc. determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026. Filing
  14. Mar 5, 2026ResultsReleased financial results. Filing
  15. Jan 8, 2026LeadershipBarbara Weber, M.D. notified the board of directors of the Company of her retirement and resignation as President and Chief Executive Officer of the Company, in each case, effective as of January 8, 2026. Filing
  16. Jan 5, 2026LeadershipThe Board of Directors of Tango Therapeutics, Inc. increased the number of directors of the Company to eight (8). Filing
  17. Nov 21, 2025AgreementTango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share, through the Agent, as sales agent. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tango Therapeutics financials

Famous investors that hold TNGX

5 of the 50 well-known investors we track reported holding TNGX in their latest 13F filing. The largest position is Ken Fisher's, worth $26.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 20261.07M$26.7M0.0%+85%
Ken Griffin · Citadel AdvisorsQ3 2026445,367$11.1M0.0%+146%
Jim Simons · Renaissance TechnologiesQ3 2026389,857$9.7M0.0%-48%
Israel Englander · Millennium ManagementQ3 2026381,372$9.5M0.0%-23%
Paul Tudor Jones · Tudor Investment CorpQ3 202686,220$2.2M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TNGX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Farallon Capital Management, L.L.C.13G/A4.9%
Nov 16, 2026TCG Crossover GP II, LLC13G/A4.6%
Nov 16, 2026Farallon Capital Management, L.L.C.13G/A4.9%
Nov 16, 2026TCG Crossover GP II, LLC13G/A4.6%
Nov 6, 2026FMR LLC13G/A15.0%
Nov 6, 2026FMR LLC13G/A15.0%

Questions about Tango Therapeutics, Inc. (TNGX) stock

Who owns the most TNGX stock?

The largest reported owner of Tango Therapeutics, Inc. (TNGX) is Rtw Investments, LP. In total, 246 funds and institutions reported holding TNGX at the end of Q2 2026. See the largest owners.

Are TNGX insiders buying or selling?

In the last 12 months, TNGX insiders reported no open-market purchases and 30 sales worth $8.1M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in TNGX?

As of Oct 30, 2026, 48.24M TNGX shares were sold short, 28.6% of the shares outstanding, up 7.7% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 9.7 trading days (days to cover). See the history.

Which famous investors hold TNGX?

5 of the 50 well-known investors we track reported TNGX in their latest 13F filing, including Ken Fisher, Ken Griffin, Jim Simons. The largest position is worth $26.7M. See all holders.

Executive pay

Tango Therapeutics's chief executive was paid a total of $2.8M for the year ended Dec 31, 2025, down 57% from $6.5M the year before. In the last 12 months, Tango Therapeutics's executives and directors bought no stock on the open market and sold $8.1M.

Chief executive, total pay$2.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$10.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.